Table 1 Pathological and clinical characteristics of BC patient series
From: CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
Variable | Frequency (%) |
|---|---|
BC subtype | |
LA | 20/142 (14.1) |
LB | 44/142 (31.0) |
LH | 33/142 (23.2) |
H | 21/142 (14.8) |
TN | 24/142 (16.9) |
Grade | |
I | 25/142 (17.6) |
II | 59/142 (41.5) |
III | 58/142 (40.8) |
Lymph node involvement | |
No | 68/139 (48.9) |
Yes | 71/139 (51.1) |
Stage | |
I | 49/138 (35.5) |
IIA | 34/138 (24.6) |
IIB | 27/138 (19.6) |
IIIA | 19/138 (13.7) |
IIIC | 9/138 (6.5) |
Age (years) | Mean 60 Range 30–95 |
Tumour size (cm) | Mean 2.2 Range 0.3–10.0 |
Progression-free survival (months) | Mean 82.9 Range 1–208 |
No | 115/141 (81.6) |
Yes | 26/141 (18.4) |
Overall survival (months) | Mean 86.9 Range 1–208 |
Exitus | 27/140 (19.3) |
Chemotherapy | |
No | 49/138 (35.5) |
Yes | 89/138 (64.5) |
Hormone therapy | |
No | 43/136 (31.6) |
Yes | 93/136 (68.4) |